Pregabalin ( DrugBank: Pregabalin )


5 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica3
36Epidermolysis bullosa1
46Malignant rheumatoid arthritis1
70Spinal stenosis6
298Hereditary pancreatitis4

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

36. Epidermolysis bullosa


Clinical trials : 163Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

46. Malignant rheumatoid arthritis


Clinical trials : 4,356Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

70. Spinal stenosis


Clinical trials : 95Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

298. Hereditary pancreatitis


Clinical trials : 95Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries